Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 4.84
NAS:SGYP's Cash-to-Debt is ranked higher than
64% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.05 vs. NAS:SGYP: 4.84 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:SGYP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.13  Med: No Debt Max: No Debt
Current: 4.84
Equity-to-Asset 0.41
NAS:SGYP's Equity-to-Asset is ranked higher than
50% of the 731 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. NAS:SGYP: 0.41 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:SGYP' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.41  Med: 0.52 Max: 0.63
Current: 0.41
0.41
0.63
Piotroski F-Score: 4
Altman Z-Score: -9.87
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -9004.35
NAS:SGYP's Operating Margin % is ranked lower than
100% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.95 vs. NAS:SGYP: -9004.35 )
Ranked among companies with meaningful Operating Margin % only.
NAS:SGYP' s Operating Margin % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: -9004.35
Net Margin % -9892.33
NAS:SGYP's Net Margin % is ranked lower than
100% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.06 vs. NAS:SGYP: -9892.33 )
Ranked among companies with meaningful Net Margin % only.
NAS:SGYP' s Net Margin % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: -9892.33
ROE % -488.30
NAS:SGYP's ROE % is ranked lower than
98% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.91 vs. NAS:SGYP: -488.30 )
Ranked among companies with meaningful ROE % only.
NAS:SGYP' s ROE % Range Over the Past 10 Years
Min: -899.32  Med: -319.1 Max: -154.96
Current: -488.3
-899.32
-154.96
ROA % -193.25
NAS:SGYP's ROA % is ranked lower than
98% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. NAS:SGYP: -193.25 )
Ranked among companies with meaningful ROA % only.
NAS:SGYP' s ROA % Range Over the Past 10 Years
Min: -6858.53  Med: -154.23 Max: -69.97
Current: -193.25
-6858.53
-69.97
ROC (Joel Greenblatt) % -35615.78
NAS:SGYP's ROC (Joel Greenblatt) % is ranked lower than
99% of the 793 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.48 vs. NAS:SGYP: -35615.78 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:SGYP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -423053.33  Med: -74545.45 Max: -666.67
Current: -35615.78
-423053.33
-666.67
3-Year EBITDA Growth Rate 13.90
NAS:SGYP's 3-Year EBITDA Growth Rate is ranked lower than
55% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. NAS:SGYP: 13.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:SGYP' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 29.2 Max: 131.7
Current: 13.9
0
131.7
3-Year EPS without NRI Growth Rate 20.10
NAS:SGYP's 3-Year EPS without NRI Growth Rate is ranked higher than
68% of the 576 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.60 vs. NAS:SGYP: 20.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:SGYP' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 29.1 Max: 122.4
Current: 20.1
0
122.4
GuruFocus has detected 3 Warning Signs with Synergy Pharmaceuticals Inc $NAS:SGYP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:SGYP's 30-Y Financials

Financials (Next Earnings Date: 2017-09-07)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

SGYP Guru Trades in Q3 2016

John Paulson 24,228,655 sh (-12.71%)
Paul Tudor Jones 18,144 sh (-47.23%)
» More
Q4 2016

SGYP Guru Trades in Q4 2016

Paul Tudor Jones 18,376 sh (+1.28%)
John Paulson 24,088,655 sh (-0.58%)
» More
Q1 2017

SGYP Guru Trades in Q1 2017

Jim Simons 56,534 sh (New)
Louis Moore Bacon 225,000 sh (New)
John Paulson 24,088,655 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q2 2017

SGYP Guru Trades in Q2 2017

Robert Bruce 100,000 sh (New)
John Paulson 24,088,655 sh (unchged)
Louis Moore Bacon 225,000 sh (unchged)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:SGYP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2017-08-07 Reduce -0.11%Premium Member Access $3.77 $ 2.91-23%24,062,368
Robert Bruce 2017-06-30 New Buy0.11%$3.39 - $4.74 $ 2.91-30%100,000
John Paulson 2016-12-31 Reduce -0.58%0.01%$4.14 - $6.09 $ 2.91-44%24,088,655
John Paulson 2016-11-04 Reduce -0.58%0.01%Premium Member Access $4.24 $ 2.91-31%24,088,655
John Paulson 2016-09-30 Reduce -12.71%0.14%$3.61 - $5.83 $ 2.91-38%24,228,655
John Paulson 2016-09-28 Reduce -0.22%Premium Member Access $5.69 $ 2.91-49%24,228,655
John Paulson 2016-09-19 Reduce -12.51%0.2%Premium Member Access $5.61 $ 2.91-48%24,282,955
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:AMPH, NAS:FLXN, NYSE:LCI, NAS:SCLN, NAS:EGRX, NAS:ACET, NAS:SCMP, NAS:HRTX, NAS:KPTI, NAS:DEPO, NAS:ADMS, NAS:TLGT, NAS:COLL, NAS:PETQ, NAS:TTPH, NAS:RIGL, NAS:DRRX, NYSE:DPLO, NAS:CPRX, NAS:TOCA » details
Traded in other countries:S90.Germany,
Headquarter Location:USA
Synergy Pharmaceuticals Inc is a manufacturer of pharmaceutical products in the United States. It develops drugs for the treatment of gastrointestinal disorders such as constipation and irritable bowel syndrome.

Synergy Pharmaceuticals Inc functions in the healthcare sector based in the United States. It focusses on developing therapies to combat gastrointestinal diseases. The company's basic ingredient is the uroguanylin analog, which it employs in its products candidates such as plecanatide and dolcanatide. Plecanatide is a once-daily tablet, which addresses chronic idiopathic constipation and the irritable bowel syndrome. Dolcanatide is meant to cure inflammatory bowel disease by aiding the process of digestive breakdown.

Top Ranked Articles about Synergy Pharmaceuticals Inc

Robert Bruce Invests in Valvoline, 2 Pharmaceutical Companies The guru exited 2 other positions in 2nd quarter
Robert Bruce (Trades, Portfolio)’s Bruce Fund gained three new positions during the second quarter and exited two others. Read more...
What Do the Ardelyx Numbers Mean for the Company? Here's a look at the latest Ardelyx data
Ardelyx Inc. (NASDAQ:ARDX) just put out data from a phase III study of its lead development asset – tenapanor. The study was the first of two planned phase IIIs with the combined data from each expected to underpin a registration submission with the Food and Drug Administration (FDA) on completion. Read more...
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Synergy Pharmaceuticals Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
John Paulson Trims Synergy Company is among many drug manufacturers in portfolio
John Paulson (Trades, Portfolio) of Paulson & Co. reduced his holdings in Synergy Pharmaceuticals (NASDAQ:SGYP) by 12.5% on Sept. 19. Read more...

Ratios

vs
industry
vs
history
PB Ratio 15.08
SGYP's PB Ratio is ranked lower than
91% of the 751 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. SGYP: 15.08 )
Ranked among companies with meaningful PB Ratio only.
SGYP' s PB Ratio Range Over the Past 10 Years
Min: 15.08  Med: 21.07 Max: 24.56
Current: 15.08
15.08
24.56
PS Ratio 291.00
SGYP's PS Ratio is ranked lower than
99.99% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. SGYP: 291.00 )
Ranked among companies with meaningful PS Ratio only.
SGYP' s PS Ratio Range Over the Past 10 Years
Min: 291  Med: 406.5 Max: 474
Current: 291
291
474
EV-to-EBIT -2.71
SGYP's EV-to-EBIT is ranked lower than
99.99% of the 559 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.11 vs. SGYP: -2.71 )
Ranked among companies with meaningful EV-to-EBIT only.
SGYP' s EV-to-EBIT Range Over the Past 10 Years
Min: -4.6  Med: -3.9 Max: -2.7
Current: -2.71
-4.6
-2.7
EV-to-EBITDA -2.72
SGYP's EV-to-EBITDA is ranked lower than
99.99% of the 587 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.50 vs. SGYP: -2.72 )
Ranked among companies with meaningful EV-to-EBITDA only.
SGYP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.6  Med: -3.9 Max: -2.7
Current: -2.72
-4.6
-2.7
Current Ratio 2.33
SGYP's Current Ratio is ranked higher than
67% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. SGYP: 2.33 )
Ranked among companies with meaningful Current Ratio only.
SGYP' s Current Ratio Range Over the Past 10 Years
Min: 0.04  Med: 3.02 Max: 11.88
Current: 2.33
0.04
11.88
Quick Ratio 2.07
SGYP's Quick Ratio is ranked higher than
73% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.82 vs. SGYP: 2.07 )
Ranked among companies with meaningful Quick Ratio only.
SGYP' s Quick Ratio Range Over the Past 10 Years
Min: 0.04  Med: 2.83 Max: 11.88
Current: 2.07
0.04
11.88
Days Inventory 421.99
SGYP's Days Inventory is ranked lower than
99% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.36 vs. SGYP: 421.99 )
Ranked among companies with meaningful Days Inventory only.
SGYP' s Days Inventory Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: 421.99
Days Sales Outstanding 269.66
SGYP's Days Sales Outstanding is ranked higher than
90% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.70 vs. SGYP: 269.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
SGYP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: 269.66
Days Payable 2.00
SGYP's Days Payable is ranked lower than
96% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.96 vs. SGYP: 2.00 )
Ranked among companies with meaningful Days Payable only.
SGYP' s Days Payable Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: 2

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -19.50
SGYP's 3-Year Average Share Buyback Ratio is ranked lower than
91% of the 473 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.10 vs. SGYP: -19.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SGYP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -248.4  Med: -21.2 Max: -14.6
Current: -19.5
-248.4
-14.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 32.33
SGYP's Price-to-Net-Cash is ranked lower than
54% of the 239 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.21 vs. SGYP: 32.33 )
Ranked among companies with meaningful Price-to-Net-Cash only.
SGYP' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 4.63  Med: 26.62 Max: 582
Current: 32.33
4.63
582
Price-to-Net-Current-Asset-Value 15.32
SGYP's Price-to-Net-Current-Asset-Value is ranked lower than
63% of the 512 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.25 vs. SGYP: 15.32 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SGYP' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4.48  Med: 19.59 Max: 301.5
Current: 15.32
4.48
301.5
Price-to-Tangible-Book 15.08
SGYP's Price-to-Tangible-Book is ranked lower than
83% of the 690 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.51 vs. SGYP: 15.08 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SGYP' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.45  Med: 19.12 Max: 597.69
Current: 15.08
4.45
597.69
Price-to-Median-PS-Value 0.71
SGYP's Price-to-Median-PS-Value is ranked lower than
99.99% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. SGYP: 0.71 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SGYP' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 1.07  Med: 1.07 Max: 1.07
Current: 0.71
Earnings Yield (Greenblatt) % -36.90
SGYP's Earnings Yield (Greenblatt) % is ranked lower than
90% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. SGYP: -36.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SGYP' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -36.8  Med: -25.55 Max: -21.7
Current: -36.9
-36.8
-21.7

More Statistics

Revenue (TTM) (Mil) $2.41
EPS (TTM) $ -1.17
Beta1.23
Short Percentage of Float29.95%
52-Week Range $2.85 - 7.15
Shares Outstanding (Mil)224.95

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 19 100 130
EPS ($) -1.11 -0.61 -0.54
EPS without NRI ($) -1.11 -0.61 -0.54
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:SGYP

Headlines

Articles On GuruFocus.com
Robert Bruce Invests in Valvoline, 2 Pharmaceutical Companies Aug 10 2017 
What Do the Ardelyx Numbers Mean for the Company? May 15 2017 
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Synergy Pharmaceuticals Inc. for P Mar 31 2017 
John Paulson Trims Synergy Sep 23 2016 
Paul Tudor Jones' Highest Performing Stocks Jul 13 2015 
Monday Pre-Market Insights: Pluristem Therapeutics, Juno Therapeutics, OraSure Technologies, Synergy May 18 2015 

More From Other Websites
Synergy Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SGYP) : August 12, 2017 Aug 11 2017
Here's Why Synergy Pharmaceuticals Inc. Is Falling Today Aug 10 2017
IHS Markit Score Update: Drop in demand for ETFs holding Synergy Pharmaceuticals Inc is a negative... Aug 10 2017
Synergy Pharmaceuticals Reports Second Quarter 2017 Financial Results and Business Update Aug 09 2017
Synergy Pharmaceuticals Inc. Tanked 14.2% in July -- but Why? Aug 08 2017
Synergy Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SGYP-US :... Jul 28 2017
ETFs with exposure to Synergy Pharmaceuticals, Inc. : July 25, 2017 Jul 25 2017
What To Expect Ahead of Synergy Pharmaceuticals Inc (SGYP) 2Q Earnings; Oppenheimer’s Take Jul 13 2017
Synergy Pharmaceuticals Inc (SGYP) Trulance Poses Enticing Long-Term Uptake Jul 10 2017
Healthcare Guru Samuel Isaly Plays Two Key Biotech Stocks: Synergy Pharmaceuticals Inc (SGPY),... Jun 27 2017
Synergy Pharmaceuticals Inc’s (SGYP) CIC Drug Set To Stay In Spotlight; BTIG Weighs In Jun 26 2017
Why This Billionaire Just Bought Gilead Sciences, Synergy, and Valeant Stock Jun 20 2017
ETFs with exposure to Synergy Pharmaceuticals, Inc. : June 15, 2017 Jun 15 2017
Synergy Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SGYP) : June 14, 2017 Jun 14 2017
Rodman & Renshaw Roots for Synergy Pharmaceuticals Inc. (SGYP) Ahead of Promising Commercial... Jun 13 2017
Synergy Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SGYP-US :... Jun 13 2017
Billionaire Israel ‘Izzy’ Englander Bets on Three Biotech Stocks: Valeant Pharmaceuticals Intl... Jun 12 2017
Synergy Pharmaceuticals Announces Acceptance of Supplemental New Drug Application (sNDA) for... Jun 07 2017
Is Ironwood's Growth About to Slow? Jun 05 2017
Today's Research Reports on Stocks to Watch: Synergy Pharmaceuticals and Bioscrip Inc. Jun 05 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}